1Drueke T: Hyporesponsiveness to recombinant human erythropoietin [J]. Nephrol Dial Transplant, 2001; 16 (Suppl. 7): 25-28.
2KDOQI, National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease [J]. Am J Kidney Dis, 2006,47 (5 Suppl 3): S11-145.
3KrauseA, NeitzS, MagertH, etal. LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity [J]. FEBS Lett, 2000,480 (2-3): 147-150.
4Ganz T. Hepcidin in iron metabolism [J]. Curr Opin Hematol, 2004, 11 (4): 251-254.
5Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation [J]. J Clin Invest, 2002,110 (7): 1037-1044.
6Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease [J]. Kidney Blood Press Res, 2007,30: 15-30.
7Tomosugi N, Kawabata H, Wakatabe R, et al. Detection of serum hepcidm in renal failure and inflammation by using Pro- teinchip System [J]. Blood, 2006,108 (4): 1381-1387.
8Ashby DR, Gale DP, Busbridge M, et al. Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease [J]. Kidney Int, 2009,75 (9): 976-981.
9Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin [J]. J Clin Invest 2004; 113: 1271-1276.
10Nemeth E, Turtle MS, Powelson J, et al. Hepcidin regulates iron efflux by binging to ferroportin and inducing its internalization [J]. Science, 2004,306: 2090-2093.
